MENU
+Compare
PACB
Stock ticker: NASDAQ
AS OF
Jun 30, 02:43 PM (EDT)
Price
$1.26
Change
-$0.03 (-2.33%)
Capitalization
976.68M

PACB Pacific Biosciences of California Forecast, Technical & Fundamental Analysis

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems... Show more

Industry: #Biotechnology
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PACB with price predictions
Jun 27, 2025

Aroon Indicator for PACB shows an upward move is likely

PACB's Aroon Indicator triggered a bullish signal on June 26, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator showed a similar pattern. In of the 196 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 03, 2025. You may want to consider a long position or call options on PACB as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PACB just turned positive on May 29, 2025. Looking at past instances where PACB's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

PACB moved above its 50-day moving average on June 06, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PACB crossed bullishly above the 50-day moving average on June 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PACB moved out of overbought territory on June 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where PACB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PACB broke above its upper Bollinger Band on June 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.393) is normal, around the industry mean (24.307). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.610) is also within normal values, averaging (42.612).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PACB is expected to report earnings to rise 17.07% to -17 cents per share on July 30

Pacific Biosciences of California PACB Stock Earnings Reports
Q2'25
Est.
$-0.18
Q1'25
Beat
by $0.04
Q4'24
Est.
$-0.20
Q3'24
Beat
by $0.05
Q2'24
Missed
by $0.41
The last earnings report on May 08 showed earnings per share of -15 cents, beating the estimate of -18 cents. With 3.93M shares outstanding, the current market capitalization sits at 976.68M.
A.I. Advisor
published General Information

General Information

a developer of sequencing system products to help scientists to resolve genetically complex problems

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1305 O’Brien Drive
Phone
+1 650 521-8000
Employees
796
Web
https://www.pacb.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIDEX13.510.11
+0.82%
Fidelity SAI Sustainable U.S. Equity Fd
AGVFX26.210.19
+0.73%
American Funds Global Insight A
DSMDX18.270.05
+0.27%
Driehaus Small/Mid Cap Growth
CGTYX78.360.19
+0.24%
Columbia Seligman Global Tech Inst3
DRRIX15.910.02
+0.13%
BNY Mellon Global Real Return - I

PACB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
N/A
MASI - PACB
58%
Loosely correlated
+0.90%
LAB - PACB
46%
Loosely correlated
-6.30%
BRKR - PACB
45%
Loosely correlated
-0.90%
ILMN - PACB
45%
Loosely correlated
+0.67%
AZTA - PACB
44%
Loosely correlated
-0.58%
More